RIGEL PHARMACEUTICALS, INC. Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Loss (Deprecated 2018-01-31)
RIGEL PHARMACEUTICALS, INC. (RIGL) reported Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Loss (Deprecated 2018-01-31) of $12.00 thousand for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-07.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses · last filed 2019-05-07
- RIGEL PHARMACEUTICALS, INC. available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate loss (deprecated 2018-01-31) for the quarter ending 2019-03-31 was $12.00K, a 86.36% decline year-over-year.
- RIGEL PHARMACEUTICALS, INC. available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate loss (deprecated 2018-01-31) for the quarter ending 2018-09-30 was -$30.00K.
- RIGEL PHARMACEUTICALS, INC. available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate loss (deprecated 2018-01-31) for the quarter ending 2018-06-30 was -$32.00K.
- RIGEL PHARMACEUTICALS, INC. available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate loss (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $88.00K, a 193.33% increase year-over-year.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Loss (Deprecated 2018-01-31) 3 month | Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Loss (Deprecated 2018-01-31) 6 month | Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Loss (Deprecated 2018-01-31) 9 month |
|---|---|---|---|
| 2019-03-31 | $12.00K 10-Q · filed 2019-05-07 | ||
| 2018-09-30 | -$30.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | -$62.00K derived: sum of 2 quarters · filed 2018-11-06 | $26.00K 10-Q · filed 2018-11-06 |
| 2018-06-30 | -$32.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $56.00K 10-Q · filed 2018-08-08 | |
| 2018-03-31 | $88.00K 10-Q · filed 2018-05-01 | ||
| 2017-09-30 | -$12.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$23.00K derived: sum of 2 quarters · filed 2017-11-07 | $7.00K 10-Q · filed 2017-11-07 |
| 2017-06-30 | -$11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-01 | $19.00K 10-Q · filed 2017-08-01 | |
| 2017-03-31 | $30.00K 10-Q · filed 2017-05-02 | ||
| 2016-03-31 | $5.00K 10-Q · filed 2016-05-03 | ||
| 2015-09-30 | -$14.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-03 | -$13.00K derived: sum of 2 quarters · filed 2015-11-03 | $4.00K 10-Q · filed 2015-11-03 |
| 2015-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $18.00K 10-Q · filed 2015-08-04 | |
| 2015-03-31 | $17.00K 10-Q · filed 2015-05-07 | ||
| 2014-09-30 | $14.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $26.00K 10-Q · filed 2014-11-04 | |
| 2014-06-30 | $12.00K 10-Q · filed 2014-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |